MIS 416 - Phase 2 interim results

A board to discuss future MS therapies in early stage (Phase I or II) trials.

MIS 416 - Phase 2 interim results

Postby Gogo » Mon Aug 20, 2012 8:44 am

" AUCKLAND, New Zealand--(BUSINESS WIRE)--

Innate Immunotherapeutics today announced positive interim data from the company’s Phase 1/2 clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS). Results of the open-label, dose-escalation/confirmation trial showed MIS416 to be well tolerated and identified a clinical dose for further evaluation. Moreover, during the dose confirmation portion of the study, 8 of 10 patients with secondary progressive MS who were treated with MIS416 for 12 weeks showed some improvement in their MS-related signs and symptoms.

“The preliminary data indicate that MIS416 was safe and well tolerated, and the MS-related clinical status assessment tools used during the study also indicate that the trial agent may have had some positive effect for many of the treated patients,” said neurologist Professor Tim Anderson, M.D., co-principal investigator for the study. “For example, 50% of the study subjects showed some improvement in EDSS scores over the relatively short 12 week duration of the trial. These interim results are encouraging and merit the consideration of a randomized controlled trial in patients with secondary progressive multiple sclerosis.” "

http://finance.yahoo.com/news/innate-an ... 00363.html
Gogo
Family Member
 
Posts: 77
Joined: Thu Aug 09, 2012 6:47 am

Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service